Padoei, Fateme and Mamsharifi, Peyman and Hazegh, Pooya and Boroumand, Homa and Ostadmohammady, Fatemeh and Abbaszadeh-Mashkani, Samira and Banafshe, Hamid Reza and Matini, Amir Hassan and Ghaderi, Amir and Dehkohneh, Somayeh Ghadami (2023) The therapeutic effect of N-acetylcysteine as an add-on to methadone maintenance therapy medication in outpatients with substance use disorders: A randomized, double-blind, placebo-controlled clinical trial. Brain and Behavior, 13 (1).
Full text not available from this repository. DOI: UNSPECIFIEDAbstract
Objective: Patients with substance use disorders (SUD) under methadone maintenance therapy (MMT) are susceptible to a number of complications (psychological and metabolic disorders). Evidence studies have shown the roles of the glutamatergic system in addiction. N-Acetylcysteine (NAC) enhances extracellular glutamate, and is effective in the treatment of neuropsychiatric disorders. We assessed oral NAC as an add-on to MMT medication for the treatment of SUD. Methods: In the current randomized, double-blind, placebo-controlled clinical trial, outpatients with SUD under MMT who were 18â��60 years old received 2400 mg/day NAC (n = 30) or placebo (n = 30) for 12 weeks. Psychological status and metabolic biomarkers were assessed at baseline and the end of the trial. Results: Compared with the placebo group, NAC treatment resulted in a significant improvement in depression score (β â��2.36; 95 CI, â��3.97, â��0.76; p =.005), and anxiety score (β â��1.82; 95 CI, â��3.19, â��0.44; p =.01). Furthermore, NAC treatment resulted in a significant elevation in total antioxidant capacity levels (β 72.28 mmol/L; 95 CI, 11.36, 133.19; p =.02), total glutathione (GSH) levels (β 81.84 μmol/L; 95 CI, 15.40, 148.28; p =.01), and a significant reduction in high-sensitivity C-reactive protein levels (β â��0.89 mg/L; 95 CI, â��1.50, â��0.28; p =.005), and homeostasis model of assessment-insulin resistance (β â��0.33; 95 CI, â��0.65, â��0.009; p =.04), compared with the placebo group. Conclusion: In the current study, improvement in depression and anxiety symptoms as well as some metabolic profiles with NAC treatment for 12 weeks in outpatients with SUD under MMT was detected.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | N-acetylcysteine,metabolic biomarker,methadone maintenance treatment,psychological status,substance use disorder |
| Subjects: | Pharmacology, Toxicology and Pharmaceutics |
| Depositing User: | editor . 5 |
| Date Deposited: | 09 Apr 2023 14:29 |
| Last Modified: | 09 Apr 2023 14:29 |
| URI: | http://eprints.kaums.ac.ir/id/eprint/7675 |
Actions (login required)
 |
View Item |
